Compare AstraZeneca plc (AZN) vs Bilibili Inc (BILI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Bilibili Inc — how do they compare? AstraZeneca plc trades at $158.39 (market cap $248.14B), while Bilibili Inc trades at $17.57 (market cap $7.65B). The key difference: AstraZeneca plc is far larger — about 32.4× Bilibili Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Bilibili Inc pays none. Which is the better fit depends on your goals.
| AZN | BILI | |
|---|---|---|
Market Cap | $248.14B | $7.65B |
Sector | Health | Media |
52-Week High | $209.48 | $35.92 |
52-Week Low | $147.06 | $15.96 |
Enterprise Value | $275.41B | $5.49B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Bilibili (BILI) trades at $17.46, down 8.06% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q1 2026 EPS of $0.19 exceeding expectations. Revenue growth remains steady at 7% year-over-year, with improving margins and a $300 million share repurchase program supporting shareholder value. Analyst sentiment remains overwhelmingly positive with 83% buy ratings.
The investment case balances strong fundamentals against technical weakness. Upside drivers include advertising growth, AI integration, and margin expansion, while risks involve competitive pressures and China's economic environment. With attractive valuation metrics and institutional support, BILI presents a compelling opportunity for patient investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →
